IFNγR signaling mediates alloreactive T-cell trafficking and GVHD
- PMID: 22972985
- PMCID: PMC3496960
- DOI: 10.1182/blood-2012-01-403196
IFNγR signaling mediates alloreactive T-cell trafficking and GVHD
Abstract
The clinical goal of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is to minimize GVHD while maintaining GvL. Here, we show that interferon γ receptor-deficient (IFNγR(-/-)) allogeneic Tconv, which possess normal alloreactivity and cytotoxicity, induce significantly less GVHD than wild-type (WT) Tconv. This effect is mediated by altered trafficking of IFNγR(-/-) Tconv to GVHD target organs, especially the gastrointestinal (GI) tract. We show that the chemokine receptor CXCR3 is induced via IFNγR-mediated signaling and partially contributes to the trafficking of WT Tconv to GVHD target organs. Indeed, CXCR3(-/-) Tconv recapitulate the reduced GVHD potential of IFNγR(-/-) Tconv in a minor-mismatched GVHD model. Most importantly, IFNγR(-/-) (and CXCR3(-/-)) Tconv mediate a robust and beneficial GvL effect. In addition, we show that IFNγR(-/-) regulatory T cells (Tregs) are fully suppressive in vitro although defective in suppressor function in vivo and that WT Tregs suppress GVHD in vivo only when allogeneic Tconv produce interferon γ (IFNγ), suggesting that the IFNγR signaling pathway is the major mechanism for both Tregs and Tconv to migrate to GVHD target organs. Finally, pharmacologic inhibition of IFNγR signaling with inhibitors of JAK1/JAK2, which are mediators of IFNγR signaling, results in the decreased expression of CXCR3 and reduced GVHD and improved survival after allo-HSCT and this effect is mediated by altered trafficking of Tconv to GVHD target organs.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3496960/bin/zh89991298600001.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3496960/bin/zh89991298600002.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3496960/bin/zh89991298600003.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3496960/bin/zh89991298600004.gif)
![Figure 5](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3496960/bin/zh89991298600005.gif)
![Figure 6](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3496960/bin/zh89991298600006.gif)
![Figure 7](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3496960/bin/zh89991298600007.gif)
Similar articles
-
Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect.PLoS One. 2014 Oct 7;9(10):e109799. doi: 10.1371/journal.pone.0109799. eCollection 2014. PLoS One. 2014. PMID: 25289677 Free PMC article.
-
Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease.Leukemia. 2018 Nov;32(11):2483-2494. doi: 10.1038/s41375-018-0123-z. Epub 2018 Apr 2. Leukemia. 2018. PMID: 29691471 Free PMC article.
-
Pharmacologic Inhibition of JAK1/JAK2 Signaling Reduces Experimental Murine Acute GVHD While Preserving GVT Effects.Clin Cancer Res. 2015 Aug 15;21(16):3740-9. doi: 10.1158/1078-0432.CCR-14-2758. Epub 2015 May 14. Clin Cancer Res. 2015. PMID: 25977345
-
The Role of Co-stimulatory/Co-inhibitory Signals in Graft-vs.-Host Disease.Front Immunol. 2018 Dec 21;9:3003. doi: 10.3389/fimmu.2018.03003. eCollection 2018. Front Immunol. 2018. PMID: 30627129 Free PMC article. Review.
-
Translational Clinical Strategies for the Prevention of Gastrointestinal Tract Graft Versus Host Disease.Front Immunol. 2021 Nov 26;12:779076. doi: 10.3389/fimmu.2021.779076. eCollection 2021. Front Immunol. 2021. PMID: 34899738 Free PMC article. Review.
Cited by
-
Novel JAK Inhibitors to Reduce Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation in a Preclinical Mouse Model.Molecules. 2024 Apr 16;29(8):1801. doi: 10.3390/molecules29081801. Molecules. 2024. PMID: 38675621 Free PMC article.
-
Addition of ruxolitinib to standard graft-versus-host disease prophylaxis for allogeneic stem cell transplantation in aplastic anemia patients.Bone Marrow Transplant. 2024 Jul;59(7):997-1005. doi: 10.1038/s41409-024-02266-7. Epub 2024 Apr 5. Bone Marrow Transplant. 2024. PMID: 38580777 Free PMC article.
-
Janus kinase inhibition in the treatment and prevention of graft-versus-host disease.Front Immunol. 2024 Feb 6;15:1304065. doi: 10.3389/fimmu.2024.1304065. eCollection 2024. Front Immunol. 2024. PMID: 38380328 Free PMC article. Review.
-
Separation of GVL from GVHD -location, location, location.Front Immunol. 2023 Dec 5;14:1296663. doi: 10.3389/fimmu.2023.1296663. eCollection 2023. Front Immunol. 2023. PMID: 38116007 Free PMC article. Review.
-
Belumosudil and ruxolitinib combination for treatment of refractory chronic graft-versus-host disease.Bone Marrow Transplant. 2024 Feb;59(2):282-284. doi: 10.1038/s41409-023-02165-3. Epub 2023 Dec 9. Bone Marrow Transplant. 2024. PMID: 38071272 No abstract available.
References
-
- Kernan NA, Collins NH, Juliano L, Cartagena T, Dupont B, O'Reilly RJ. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood. 1986;68(3):770–773. - PubMed
-
- Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol. 2007;7(5):340–352. - PubMed
-
- Butturini A, Bortin MM, Gale RP. Graft-versus-leukemia following bone marrow transplantation. Bone Marrow Transplant. 1987;2(3):233–242. - PubMed
-
- Butturini A, Gale RP. The role of T-cells in preventing relapse in chronic myelogenous leukemia. Bone Marrow Transplant. 1987;2(4):351–354. - PubMed
-
- Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003;9(9):1144–1150. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous